| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
The objective in this study is to elucidate mechanism of drug-induced rhabdomyolysis in patients with end-stage kidney disease. In this study, we showed that uremic toxins, accumulated in patients with end-stage kidney disease, induce the functional decrease of metabolic enzyme (Cytochrome P450) with many drugs. In addition, we showed that uremic toxins increase drug-induced rhabdomyolysis by lipid-lowering agent (statins), and the increase results from the decrease in mevalonate and geranylgeranyl pyrophosphate. These results suggest that addition of mevalonate and geranylgeranyl pyrophosphate is useful for avoidance of statin-induced rhabdomyolysis in patients with end-stage kidney disease.
|
